Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment

Autores de CIPF
Participantes ajenos a CIPF
- Balzano-Nogueira L
- Huertas-López F
Grupos de Investigación
Abstract
The intrinsic characteristics of the tumor microenvironment (TME), including acidic pH and overexpression of hydrolytic enzymes, offer an exciting opportunity for the rational design of TME-drug delivery systems (DDS). We developed and characterized a pH-responsive biodegradable poly-L-glutamic acid (PGA)-based combination conjugate family with the aim of optimizing anticancer effects. We obtained combination conjugates bearing Doxorubicin (Dox) and aminoglutethimide (AGM) with two Dox loadings and two different hydrazone pH sensitive linkers that promote the specific release of Dox from the polymeric backbone within the TME. Low Dox loading coupled with a short hydrazone linker yielded optimal effects on primary tumor growth, lung metastasis (-90% reduction), and toxicological profile in a preclinical metastatic triple-negative breast cancer (TNBC) murine model. The use of transcriptomic analysis helped us to identify the molecular mechanisms responsible for such results including a differential immunomodulation and cell death pathways among the conjugates. This data highlights the advantages of targeting the TME, the therapeutic value of polymer-based combination approaches, and the utility of -omits-based analysis to accelerate anticancer DDS.
Datos de la publicación
- ISSN/ISSNe:
- 0142-9612, 1878-5905
- Tipo:
- Article
- Páginas:
- 8-21
- PubMed:
- 30278346
BIOMATERIALS ELSEVIER SCI LTD
Citas Recibidas en Web of Science: 60
Documentos
- No hay documentos
Filiaciones
Keywords
- Polymer therapeutics; Polypeptides; Tumor microenvironment; Polymer-based combination conjugates; Metastatic triple-negative breast cancer; Transcriptomics
Proyectos asociados
Towards the design of Personalised Polymer-based Combiantion Nanomedicines for Advanced Stage Breast Cancer Patients
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2015
Caracterización molecular de células propagadoras de cáncer de pulmón como herramienta predictiva y para el diseño de terapias personalizadas
Investigador Principal: ROSA M FARRÀS RIVERA
INSTITUTO DE SALUD CARLOS III . 2016
Nuevos métodos para los retos emergentes en el análisis de datos de secuenciación masiva
Investigador Principal: SONIA TARAZONA CAMPOS
MINISTERIO DE ECON. Y COMPET. . 2015
Polímeros Terapéuticos diseñados para cruzar la Barrera Hematoencefálica para el tratamiento de desordenes neurodegenerativos-Explorando la Ruta Intranasal.
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE ECON. Y COMPET. . 2016
Combinatory treatment of Neural precursor cells and a new nanoconjugate of Fasudil for the clinical application in Acute Spinal Cord Injury
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACION LA MARATO DE TV3 . 2018
Estudio del papel de la GTPasa RAB11 en cáncer de próstata para su uso como biomarcador
Investigador Principal: ANA ARMIÑAN DE BENITO
CONSELLERIA DE EDUCACION . 2018
RTC-2017-6600-1 Desarrollo de una plataforma de terapia génica para enfermedades genéticas renales
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018
Desarrollo de terapias tópicas basadas en sistemas de transporte polipeptídicos
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018
Biomarcadores para oncología de precisión en cáncer de Pulmón, Colorrectal y Melanoma
Investigador Principal: CARMEN ESPINÓS ARMERO
AGENCIA VALENCIANA DE INNOVACIÓN . 2018